SEC Filings
Eton’s ET-700 Cuts Side Effects In Pilot Study, But GALZIN Blocks More Copper
Eton intends to test faster-release formulations in 2027 after preliminary results from a four-week study in healthy volunteers.
ETON
Eton Pharmaceuticals (ETON) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Eton Sets $57.9 Million Sales Record And Lifts Its 2026 Revenue Outlook
The rare-disease drug company expects more than $175 million in annual sales and an adjusted earnings margin of at least 40%.
Earnings
Eton CEO Says Pipeline Will Make Today's Record Business Look 'Inconsequential' Within A Few Years
Eton's CEO pitched nine pipeline programs and bigger deals after revenue of $57.9 million, and explained why guidance stays conservative.
SEC Filings
Eton Pays $10.0 Million Upfront For U.S. Rights To Aquestive's Libervant, With Up To $47.5 Million More In Milestones
The license adds a mid-teens royalty and a 20-year supply deal, and Eton anticipates an April 2027 launch, subject to final FDA approval.